CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Hoang from Citi maintained a Hold rating on the stock ...

March 17 (Reuters) - Shares of Sarepta Therapeutics Inc (SRPT.O), opens new tab slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S ...

William Blair notes that Sarepta Therapeutics Inc.’s SRPT Elevidys, supported by its expanded label, is expected to generate approximately $700 million annually in revenue for fiscal years 2025 ...